Live Biotherapeutic Products – a new regulatory approach for the safety assessment of a specific category of biological medicinal products

An article has been published in Frontiers in Medicine: Regulatory Science section, which proposes a new set of recommendations for addressing the various regulatory and technical challenges when assessing the safety of Live Biotherapeutic Products (LBPs). The publication represents the result of several face-to-face discussion sessions organized by the Pharmabiotic Research Institute (PRI).

Increased understanding of the relationship between the microbiota and its host highlighted the therapeutic potential of selected microorganisms to prevent or treat disease. However, while the pharmaceutical regulatory framework is harmonized at the EU level, obtaining a marketing authorization for LBPs remains very challenging. The safety assessment itself poses particular problems because of the potential sensitivity of the target population, the “live” nature and the complicated mode of action of LBPs.

While pharmaceutical guidelines for other biological products can be taken into account to design the relevant (non-)clinical development programmes, adapted guidelines on the safety assessment for LBPs are scattered and diverse. The authors of this article have made a concerted effort to establish a risk assessment roadmap for LBPs and propose appropriate solutions for non-clinical programmes and First in Human clinical safety trials.

“As developers have struggled when designing their LBP pre-clinical programmes, the industry can benefit from this very practical road map which takes into account the new concepts of ‘quality’ and ‘development-by-design’, usually applied to other biological medicinal products,”

says Dr. Magali Cordaillat-Simmons, corresponding author on the paper and Executive Director of the PRI.

Pr. Bruno Pot, Science Director for Yakult Europe and President of the PRI underlines,

“The current paper is thought to respond to a real need in the field. Product developers, medical doctors, pharmacists, and patients might all benefit from clear procedures for the development of LBPs. The article could also help in the development of future regulatory pathways that will guarantee safety of LBPs for vulnerable populations, possibly helping groups of patients with high unmet medical needs.”

The resulting document provides recommendations on regulatory approaches that will meet the drug authorities’ expectations, weighing the existing guidelines for other biological drugs, but also focusing on strain characterization, involving history of use, antibiotic resistance and virulence testing, translocation potential, particular metabolic activities and potential drug-drug interactions. The paper reviews some newly developed research tools that could be considered, although often not yet validated. The approach proposed is largely supported by academic and industry representatives and will support future LBP safety assessment studies in Europe and the US.

Research article published in Frontiers in Medicine: Live Biotherapeutic Products, a road map for safety assessment

About the PRI

The Pharmabiotic Research Institute (PRI) is a neutral and financially independent non-profit association (according to French law: Association loi 1901), who believes that the microbiome is the future of human medicine. The PRI applies a unique collaborative approach to improve market access and provide technical and regulatory intelligence for its membersin the microbiome & human health space. Understanding themicrobiome and its role in human health, however, represents a paradigm shift in how medicines will be developed, as innovation and industry often outpace regulation. The PRI was founded to make Microbiotic Medicinal Products (MMPs) a therapeutic reality in Europe. Our mission is to facilitate the conversation between European regulators and MMP developers and their partners. By being themain representative organization interrogated by the competent authorities regarding the future regulatory framework for MMPs, the PRI has become the first network for the European microbiome pharmaceutical supply chain, federating fundamental actors from the industry, such as stakeholders involved in the development, investment, production and commercialization of MMPs.